NAVB Stock Overview A biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. More details
Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Navidea Biopharmaceuticals, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Navidea Biopharmaceuticals Historical stock prices Current Share Price US$0.0001 52 Week High US$0.13 52 Week Low US$0.000001 Beta 1.15 1 Month Change 0% 3 Month Change -90.00% 1 Year Change -99.81% 3 Year Change -99.99% 5 Year Change -99.99% Change since IPO -100.00%
Recent News & Updates
Navidea Biopharmaceuticals, Inc. Announces Results of Exploratory Analysis Completed on July 2, 2024 Jul 04
Navidea Biopharmaceuticals, Inc. Announces Board Resignations Jun 21
Navidea Biopharmaceuticals, Inc. Files Form 15 Jan 27 Navidea Biopharmaceuticals, Inc., Annual General Meeting, Nov 16, 2023 Navidea Biopharmaceuticals Requests Oral Hearing with NYSE Hearing Panel NYSE American Determines to Commence Proceedings to Delist the Common Stock of Navidea Biopharmaceuticals Jul 31
See more updates
Navidea Biopharmaceuticals, Inc. Announces Results of Exploratory Analysis Completed on July 2, 2024 Jul 04
Navidea Biopharmaceuticals, Inc. Announces Board Resignations Jun 21
Navidea Biopharmaceuticals, Inc. Files Form 15 Jan 27 Navidea Biopharmaceuticals, Inc., Annual General Meeting, Nov 16, 2023 Navidea Biopharmaceuticals Requests Oral Hearing with NYSE Hearing Panel NYSE American Determines to Commence Proceedings to Delist the Common Stock of Navidea Biopharmaceuticals Jul 31
Navidea Biopharmaceuticals, Inc. Announces Executive Changes Jul 30
Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer Jul 28
Navidea Biopharmaceuticals, Inc. Announces Board Changes Jul 14
Navidea Biopharmaceuticals Proposes Reverse Stock Split, Stock-For-Debt Swap to End Its Threat of De-Listing Jul 07
New major risk - Shareholder dilution Jul 06
High number of new and inexperienced directors Jul 01
Navidea Biopharmaceuticals Receives NYSE American Notice Jun 03
Navidea Biopharmaceuticals, Inc. Announces Board Changes Jun 02
Navidea Biopharmaceuticals, Inc. Promotes Michael Sherman Blue, M.D., FACEP, to Chief Medical Officer May 12
Navidea Biopharmaceuticals, Inc. to Report Q1, 2023 Results on May 12, 2023 May 09
Full year 2022 earnings released: US$0.56 loss per share (vs US$0.40 loss in FY 2021) Mar 22
Navidea Biopharmaceuticals Announces the Notice of Allowance for U.S. Patent Application for Key Component of the Cancer Immunotherapy Pipeline Jan 04
Navidea Biopharmaceuticals, Inc. and Macrophage Therapeutics, Inc. Files Appeal in CRG Case Dec 01
Navidea Biopharmaceuticals, Inc. Announces 50th Participant Enrolled in the its Phase 3 Trial in Rheumatoid Arthritis Nov 29
Third quarter 2022 earnings released: US$0.25 loss per share (vs US$0.081 loss in 3Q 2021) Nov 16
High number of new and inexperienced directors Nov 16
High number of new and inexperienced directors Nov 01 Navidea Biopharmaceuticals, Inc., Annual General Meeting, Dec 08, 2022
Navidea Biopharmaceuticals, Inc. Announces Results from the Completed NAV3-31 Phase 2B Clinical Study as Well as the Preliminary Results of Its Ongoing NAV3-32 Phase 2B Study At Annual Meeting of the American College of Rheumatology Sep 16 Navidea Biopharmaceuticals, Inc. and Macrophage Therapeutics Inc. Announces Court Made an Oral Ruling from Bench in Open Court At the Conclusion of the Trial in Case No. 2018-24442-151 Navidea Biopharmaceuticals, Inc. has completed a Composite Units Offering in the amount of $14.2 million. Aug 27
Second quarter 2022 earnings released: US$0.099 loss per share (vs US$0.092 loss in 2Q 2021) Aug 16
Navidea Biopharmaceuticals, Inc. Announces Publication of Study Examining Use of Tc99m Tilmanocept for Lymphatic Mapping and Sentinel Lymph Node Biopsy in Melanoma and Oral Cancer in Australia Aug 02
Navidea Biopharmaceuticals, Inc. Announces Publication of Study Examining Tc99m Tilmanocept Imaging of Arterial Inflammation in People with HIV Jul 26
First quarter 2022 earnings released: US$0.099 loss per share (vs US$0.11 loss in 1Q 2021) May 13
High number of new and inexperienced directors Apr 27
Navidea Biopharmaceuticals, Inc. Announces Positive Preliminary Results of its Ongoing Phase 2B Study Comparing Tc99m Tilmanocept Imaging with Histopathology of Joints from Patients with Rheumatoid Arthritis Apr 21
Navidea Biopharmaceuticals Announces the Regulatory Approval of Lymphoaim in India Apr 19
Navidea Biopharmaceuticals Receives Acceptance Letter from Nyse American Apr 13
Navidea Biopharmaceuticals Announces Executive Changes Apr 08 Navidea Biopharmaceuticals Announces Receipt of Noncompliance Notice from NYSE American
Forecast to breakeven in 2024 Jan 02
Navidea Biopharmaceuticals, Inc. Announces Launch of Phase 3 Clinical Trial in Rheumatoid Arthritis Dec 17
Navidea Biopharmaceuticals Completes Full Enrollment in Phase 2b Normative Database Study to Support its Rheumatoid Arthritis Programram Dec 16
Navidea Biopharmaceuticals, Inc. Provides Update on Litigation with Capital Royalty Partners II L.P Nov 27
Third quarter 2021 earnings released: US$0.081 loss per share (vs US$0.13 loss in 3Q 2020) Nov 13
High number of new and inexperienced directors Nov 03
High number of new and inexperienced directors Oct 02
Independent Director Claudine Bruck has left the company Sep 19
Independent Chairman of the Board Sarah Rouan has left the company Sep 19
Consensus revenue estimates increase to US$9.39m Aug 19
Second quarter 2021 earnings released: US$0.092 loss per share (vs US$0.11 loss in 2Q 2020) Aug 13
Navidea Biopharmaceuticals Announces First 110 Subjects Imaged in NAV3-35 Normative Database Phase 2b Study to Support Rheumatoid Arthritis Indications Jul 20
Navidea Biopharmaceuticals Announces End-of-Phase 2 Type B Meeting Request Granted by the FDA to Discuss Ongoing Clinical Program in Rheumatoid Arthritis Jul 16
John K. Scott Requests Navidea Biopharmaceuticals to Appoint Two Additional Members to the Board Jun 16
Consensus forecasts updated May 18
Chief Business Officer has left the company May 16
Full year 2020 earnings released: US$0.48 loss per share (vs US$0.76 loss in FY 2019) Mar 26
Navidea Biopharmaceuticals, Inc. announced that it expects to receive $5 million in funding Mar 04
Need To Know: Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB) Insiders Have Been Buying Shares Feb 10
Navidea Biopharmaceuticals, Inc. Announces Submission of Formal Type B Meeting Request with FDA and Launch of NAV3-32 Phase 2B Trial in Rheumatoid Arthritis Feb 09
New 90-day high: US$2.89 Feb 05
Navidea Biopharmaceuticals Strengthens Board of Directors with the Appointment of Malcolm Witter Dec 29
New 90-day low: US$2.16 Dec 08
Revenue and earnings beat expectations Nov 15
Third quarter 2020 earnings released: US$0.13 loss per share Nov 15
Navidea Biopharmaceuticals Announces Positive Results Encompassing Additional Patients from Its Ongoing Phase 2B Study in Rheumatoid Arthritis Nov 13
New 90-day low: US$2.21 Nov 11
New 90-day low: US$2.58 Oct 20
Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation At the American College of Rheumatology Annual Meeting Oct 11
New 90-day low: US$2.64 Oct 02
Analysts lower revenue estimates to US$763.5k Aug 21
First half earnings released Aug 14
Navidea Biopharmaceuticals, Inc. announced that it has received $1 million in funding from Jubilant Pharma Limited Aug 11
New 90-day high - US$4.87 Jul 21 Shareholder Returns NAVB US Biotechs US Market 7D 0% -2.7% -2.6% 1Y -99.8% -6.2% 23.1%
See full shareholder returns
Return vs Industry: NAVB underperformed the US Biotechs industry which returned -5% over the past year.
Return vs Market: NAVB underperformed the US Market which returned 22.4% over the past year.
Price Volatility Is NAVB's price volatile compared to industry and market? NAVB volatility NAVB Average Weekly Movement 90.7% Biotechs Industry Average Movement 10.7% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.8% 10% least volatile stocks in US Market 3.1%
Stable Share Price: NAVB's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: NAVB's weekly volatility has decreased from 909007% to 91% over the past year, but is still higher than 75% of US stocks.
About the Company Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases.
Show more Navidea Biopharmaceuticals, Inc. Fundamentals Summary How do Navidea Biopharmaceuticals's earnings and revenue compare to its market cap? NAVB fundamental statistics Market cap US$10.00k Earnings (TTM ) -US$8.81m Revenue (TTM ) US$610.00
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) NAVB income statement (TTM ) Revenue US$610.00 Cost of Revenue US$50.04k Gross Profit -US$49.43k Other Expenses US$8.77m Earnings -US$8.81m
Last Reported Earnings
Sep 30, 2023
Earnings per share (EPS) -0.088 Gross Margin -8,102.62% Net Profit Margin -1,444,993.44% Debt/Equity Ratio -41.9%
How did NAVB perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/31 18:01 End of Day Share Price 2024/12/31 00:00 Earnings 2023/09/30 Annual Earnings 2022/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Navidea Biopharmaceuticals, Inc. is covered by 10 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Raghuram Selvaraju Aegis Capital Corporation Robert Wasserman Dawson James Securities Michael King Dawson James Securities
Show 7 more analysts 
